Who makes metronidazole hydrogel?

metronidazole hydrogel is developed by University of L'Aquila.

What development phase is metronidazole hydrogel in?

metronidazole hydrogel is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

metronidazole hydrogel

University of L'Aquila · FDA-approved active Small molecule Quality 2/100

Metronidazole hydrogel, developed by the University of L'Aquila, is a marketed topical treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its unique formulation, which may offer enhanced efficacy and patient compliance compared to existing treatments. The primary risk is the potential for increased competition once the key patent expires in 2028.

At a glance

Generic name	metronidazole hydrogel
Also known as	Non Surgical Periodontal Therapy
Sponsor	University of L'Aquila
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Metronidazole Hydrogel 25% in Stage II and III Periodontitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

metronidazole hydrogel CI brief — competitive landscape report
metronidazole hydrogel updates RSS · CI watch RSS
University of L'Aquila portfolio CI